Yellow Fever - Pipeline Review, H2 2020
Yellow Fever - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Pipeline Review, H2 2020, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.
Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.
Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Yellow Fever - Pipeline Review, H2 2020, provides an overview of the Yellow Fever (Infectious Disease) pipeline landscape.
Yellow fever is an acute systemic illness (hemorrhagic fever) caused by the Flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeats, bleeding, vomiting, coma, delirium, fever, headache and muscle aches. There is no specific treatment for yellow fever but can be treated to relieve the symptoms.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Yellow Fever - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Yellow Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively.
Yellow Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Yellow Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Yellow Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Yellow Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Yellow Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Yellow Fever (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Yellow Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Yellow Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Yellow Fever - Overview
Yellow Fever - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Yellow Fever - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Yellow Fever - Companies Involved in Therapeutics Development
Bavarian Nordic A/S
BioCryst Pharmaceuticals Inc
Curevac AG
Emergex Vaccines Holding Ltd
Ennaid Therapeutics LLC
Fab’entech SA
iBio Inc
Imutex Ltd
Medigen Inc
Najit Technologies Inc
Orgenesis Inc
Sanofi
Serum Institute of India Ltd
Smart Biotech LLC
Tychan Pte Ltd
Yellow Fever - Drug Profiles
AGS-v PLUS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galidesivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hydrovax-YFV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SinSaVak - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Yellow Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccines for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Yellow Fever - Dormant Projects
Yellow Fever - Product Development Milestones
Featured News & Press Releases
Aug 19, 2020: Emergex and Bio-Manguinhos/Fiocruz elucidate T cell epitopes produced by commercial yellow fever vaccine
Jul 30, 2020: SMART Researchers develop potential antibody treatment for yellow fever in seven months
Jul 29, 2020: NEJM study demonstrates safety and efficacy of first novel monoclonal antibody specifically developed to treat yellow fever
Nov 18, 2019: WuXi Biologics congratulates Tychan on the world's first yellow fever antibody tested safe and efficacious in human volunteers
May 09, 2019: BioCryst completes Phase 1 clinical trial of galidesivir
Jan 02, 2019: BioCryst initiates phase 1 clinical trial of Galidesivir
Dec 13, 2018: WuXi Biologics congratulates Tychan on first-in-class monoclonal antibody for Yellow fever after record 7 months of development
Dec 06, 2018: Tychan Begins Phase I Trials for First Ever Yellow Fever Drug
Sep 17, 2018: BioCryst receives additional $3.5 million to fund clinical trials of Galidesivir in Yellow Fever
Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Yellow Fever - Overview
Yellow Fever - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Yellow Fever - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Yellow Fever - Companies Involved in Therapeutics Development
Bavarian Nordic A/S
BioCryst Pharmaceuticals Inc
Curevac AG
Emergex Vaccines Holding Ltd
Ennaid Therapeutics LLC
Fab’entech SA
iBio Inc
Imutex Ltd
Medigen Inc
Najit Technologies Inc
Orgenesis Inc
Sanofi
Serum Institute of India Ltd
Smart Biotech LLC
Tychan Pte Ltd
Yellow Fever - Drug Profiles
AGS-v PLUS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMX-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galidesivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hydrovax-YFV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SinSaVak - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Yellow Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccines for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
yellow fever vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Yellow Fever - Dormant Projects
Yellow Fever - Product Development Milestones
Featured News & Press Releases
Aug 19, 2020: Emergex and Bio-Manguinhos/Fiocruz elucidate T cell epitopes produced by commercial yellow fever vaccine
Jul 30, 2020: SMART Researchers develop potential antibody treatment for yellow fever in seven months
Jul 29, 2020: NEJM study demonstrates safety and efficacy of first novel monoclonal antibody specifically developed to treat yellow fever
Nov 18, 2019: WuXi Biologics congratulates Tychan on the world's first yellow fever antibody tested safe and efficacious in human volunteers
May 09, 2019: BioCryst completes Phase 1 clinical trial of galidesivir
Jan 02, 2019: BioCryst initiates phase 1 clinical trial of Galidesivir
Dec 13, 2018: WuXi Biologics congratulates Tychan on first-in-class monoclonal antibody for Yellow fever after record 7 months of development
Dec 06, 2018: Tychan Begins Phase I Trials for First Ever Yellow Fever Drug
Sep 17, 2018: BioCryst receives additional $3.5 million to fund clinical trials of Galidesivir in Yellow Fever
Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine
Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Yellow Fever, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Yellow Fever - Pipeline by Bavarian Nordic A/S, H2 2020
Yellow Fever - Pipeline by BioCryst Pharmaceuticals Inc, H2 2020
Yellow Fever - Pipeline by Curevac AG, H2 2020
Yellow Fever - Pipeline by Emergex Vaccines Holding Ltd, H2 2020
Yellow Fever - Pipeline by Ennaid Therapeutics LLC, H2 2020
Yellow Fever - Pipeline by Fab’entech SA, H2 2020
Yellow Fever - Pipeline by iBio Inc, H2 2020
Yellow Fever - Pipeline by Imutex Ltd, H2 2020
Yellow Fever - Pipeline by Medigen Inc, H2 2020
Yellow Fever - Pipeline by Najit Technologies Inc, H2 2020
Yellow Fever - Pipeline by Orgenesis Inc, H2 2020
Yellow Fever - Pipeline by Sanofi, H2 2020
Yellow Fever - Pipeline by Serum Institute of India Ltd, H2 2020
Yellow Fever - Pipeline by Smart Biotech LLC, H2 2020
Yellow Fever - Pipeline by Tychan Pte Ltd, H2 2020
Yellow Fever - Dormant Projects, H2 2020
Yellow Fever - Dormant Projects, H2 2020 (Contd..1), H2 2020
Number of Products under Development for Yellow Fever, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Yellow Fever - Pipeline by Bavarian Nordic A/S, H2 2020
Yellow Fever - Pipeline by BioCryst Pharmaceuticals Inc, H2 2020
Yellow Fever - Pipeline by Curevac AG, H2 2020
Yellow Fever - Pipeline by Emergex Vaccines Holding Ltd, H2 2020
Yellow Fever - Pipeline by Ennaid Therapeutics LLC, H2 2020
Yellow Fever - Pipeline by Fab’entech SA, H2 2020
Yellow Fever - Pipeline by iBio Inc, H2 2020
Yellow Fever - Pipeline by Imutex Ltd, H2 2020
Yellow Fever - Pipeline by Medigen Inc, H2 2020
Yellow Fever - Pipeline by Najit Technologies Inc, H2 2020
Yellow Fever - Pipeline by Orgenesis Inc, H2 2020
Yellow Fever - Pipeline by Sanofi, H2 2020
Yellow Fever - Pipeline by Serum Institute of India Ltd, H2 2020
Yellow Fever - Pipeline by Smart Biotech LLC, H2 2020
Yellow Fever - Pipeline by Tychan Pte Ltd, H2 2020
Yellow Fever - Dormant Projects, H2 2020
Yellow Fever - Dormant Projects, H2 2020 (Contd..1), H2 2020
LIST OF FIGURES
Number of Products under Development for Yellow Fever, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
Number of Products under Development for Yellow Fever, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
